NASDAQ: BCABBioatla Inc Stock
$0.32+0.00 (+0%)
Updated Apr 17, 2025
BCAB Price
$0.32
Fair Value Price
$0.66
Market Cap
$18.92M
52 Week Low
$0.24
52 Week High
$3.53
P/E
-0.23x
P/B
1.33x
P/S
2.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.00M
Earnings
-$69.78M
Gross Margin
100%
Operating Margin
-634.33%
Profit Margin
-634.3%
Debt to Equity
2.68
Operating Cash Flow
-$72M
Beta
1.83
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BCAB Overview
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCAB's potential to beat the market
- BCAB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCAB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important BCAB news, forecast changes, insider trades & much more!
BCAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCAB ($0.32) is undervalued by 50.55% relative to our estimate of its Fair Value price of $0.66 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BCAB ($0.32) is significantly undervalued by 50.55% relative to our estimate of its Fair Value price of $0.66 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCAB due diligence checks available for Premium users.
Valuation
BCAB fair value
Fair Value of BCAB stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$0.66
Undervalued by
51.16%
BCAB ($0.32) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCAB ($0.32) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.23x
Industry
-177.72x
Market
27.98x
BCAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.33x
Industry
4.05x
BCAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BCAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.9M
Profit Margin
0%
BCAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BCAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$52.4M
Liabilities
$38.2M
Debt to equity
2.68
BCAB's short-term assets ($51.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCAB's short-term assets ($51.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCAB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$0.0
Financing
$9.3M
BCAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCAB vs Biotech Stocks
Bioatla Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.